purpose: to study the effects of adding intravitreal bevacizumab (avastin) to conventional laser treatment on regression of retinal neovascularization in threshold rop. methods: intravitreal injection of bevacizumab (1.25 mg) in one eye of each of three newborns with threshold rop was performed in addition to laser treatment. the other eye of each patient was treated with laser alone. changes i...

OBJECT The FDA approval of bevacizumab for recurrent glioblastoma has resulted in its increased use in this patient population. Phase II trials reported 4%-6% impaired wound healing for bevacizumab initiated postoperatively. The effect of preoperative bevacizumab on subsequent craniotomy healing has not been addressed. METHODS The authors retrospectively reviewed the cases of patients who und...

BACKGROUND The impact of bevacizumab on functional recovery and histology of the liver was evaluated in patients undergoing hepatic resection for colorectal liver metastases (CLM) following bevacizumab treatment. METHODS Consecutive patients who had resection of CLM between July 2005 and July 2009 following preoperative chemotherapy were identified retrospectively from a prospectively collect...

We developed a point-of-care testing method based on lateral flow assay for bevacizumab, using an anti-idiotypic DNA aptamer as the capture molecule. Bevacizumab loaded onto sample pad strip bound to red-colored aptamer-modified gold nanoparticles (AuNPs) in conjugation and then migrated into developing zone. The AuNPs bevacizumab were trapped by protein A test spot. In contrast, excess amounts...

PURPOSE To determine the serum concentrations of bevacizumab and vascular endothelial growth factor (VEGF) in infants with retinopathy of prematurity (ROP) who received intravitreal bevacizumab; and to determine whether the changes in the serum concentration of bevacizumab were significantly correlated with the serum concentration of VEGF after intravitreal bevacizumab. DESIGN Case series. ...

BACKGROUND This randomized phase II trial investigated the efficacy and safety of capecitabine/oxaliplatin (CapOx) plus bevacizumab and dose-modified capecitabine/irinotecan (mCapIri) plus bevacizumab as first-line therapy in patients with metastatic colorectal cancer (mCRC). PATIENTS AND METHODS Patients received bevacizumab 7.5 mg/kg with oxaliplatin 130 mg/m(2)/day 1 plus capecitabine 1000...

Abstract: Title: Teratogenic Effects of Intravitreal Injection of Bevacizumab in Pregnant Rat Models Aim: To investigate teratogenic effect of intravitreal injection of bevacizumab in pregnant rat model Methods: Twenty seven female Wistar rat were inseminated. Pregnant rats were divided into 6 groups (three groups as case and three as control groups). Each case and control groups divided accord...

BACKGROUND Manifold data have demonstrated that the addition of bevacizumab to chemotherapy improved progression-free survival (PFS), while few trials have revealed its significant overall survival (OS) benefit. Furthermore, it still remains suspended how to maximize the benefits of bevacizumab as first-line therapy for human epidermal growth factor receptor 2 (HER2)-negative breast cancer. We ...

this study determined the clinical effect of subconjunctival administration of bevacizumab in patients with primary and recurrent pterygium. the study was an off-label, single-dosing, interventional case series involving 22 patients with primary and recurrent pterygium. they received subconjunctival bevacizumab (0.2cc). pterygium vascularity and thickness was graded. the size of the pterygium (...